Memo Therapeutics
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB platform creates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Domain
memo-therapeutics.com
Country
SwitzerlandIndustry
BiotechnologyEmployees
11-50
Last Funding
$22.0M
Founded
2011
No technologies detected yet for this company.
Frequently Asked Questions
What technologies does Memo Therapeutics use?+
We have not yet detected technologies for Memo Therapeutics.
What industry is Memo Therapeutics in?+
Memo Therapeutics operates in the Biotechnology industry.
Where is Memo Therapeutics based?+
Memo Therapeutics is headquartered in Switzerland.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026